Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

A sight loss organisation’s services in Scotland have been awarded a cash boost of nearly £100,000 for the next three years.

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...